Please use this identifier to cite or link to this item:
|Title:||Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients||Authors:||Back, Michael ;Eade, Thomas ;Charles, K.A.;Harris, B.D.;Haddad, C.R.;Clarke, S.J.;Guminksi, A.;Stevens, M.;Dodds, T.;Gill, Anthony J ;Veivers, D.||Affliation:||Central Coast Local Health District||Issue Date:||Feb-2016||Source:||Volume 18, Issue 16, pp. 124||Journal title:||BMC Cancer||Department:||Radiation Oncology
Central Coast Cancer Centre
|Abstract:||BACKGROUND: Currently there are very few biomarkers to identify head and neck squamous cell carcinoma (HNSCC) cancer patients at a greater risk of recurrence and shortened survival. This study aimed to investigate whether a marker of systemic inflammation, the neutrophil-to-lymphocyte ratio (NLR), was predictive of clinical outcomes in a heterogeneous cohort of HNSCC cancer patients. METHODS: We performed a retrospective analysis to identify associations between NLR and clinicopathological features to recurrence free survival (RFS) and overall survival (OS). Univariate analysis was used to identify associations and selected variables were included in multivariable Cox regression analysis to determine predictive value. RESULTS: A total of 145 patients with stage I-IV HNSCC that had undergone radiotherapy were analysed. Seventy-six of these patients had oropharyngeal cancer and 69 had non-oropharyngeal HNSCC and these populations were analysed separately. NLR was not associated to any clinicopathological variable. On univariate analysis, NLR showed associations with RFS and OS in both sub-populations. Multivariable analysis showed patients with NLR > 5 had shortened OS in both sub-populations but NLR > 5 only predicted RFS in oropharyngeal patients. Poor performance status predicted OS in both sub-populations and current smokers had shortened OS and RFS in non-oropharyngeal patients. CONCLUSIONS: The results show patients with NLR > 5 predict for shorter overall survival. Further prospective validation studies in larger cohorts are required to determine the clinical applicability of NLR for prognostication in HNSCC patients.||URI:||https://elibrary.cclhd.health.nsw.gov.au/cclhdjspui/handle/1/1238||DOI:||10.1186/s12885-016-2089-4||Pubmed:||https://www.ncbi.nlm.nih.gov/pubmed/26892430||ISSN:||1471-2407||Publicaton type:||Journal Article||Keywords:||Neoplasms
|Appears in Collections:||Oncology / Cancer|
Show full item record
checked on Jun 9, 2023
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.